In vivo, OX40L acts as a costimulator, significantly increasing CD4+ and CD8+ T cells. OX40L mRNA‐LNPs reduced tumor growth and increased the survival of mice bearing H22 tumors. This evidence concerns the gene CD8A and neoplasm.